Natco Pharma Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

- Natco Pharma is actively pursuing acquisitions to diversify revenue and reduce earnings volatility. - The company has been working on expanding globally with investments in Brazil, Canada, South Africa, Indonesia, and the U.S. - South Africa investment is expected to take 3-4 years to yield returns; other international operations (Brazil, Canada) are in various stages of profitability. - Natco's strategy focuses on building a global company with geographical diversification. - Management prefers deploying cash on strategic acquisitions over share buybacks to strengthen core business and global footprint. - Long gestation period for investments (5-7 years for building from scratch, 2-3 years if through acquisition). - R&D expenditure expected at 7%-9% going forward, supporting long-term product pipeline and filings. Overall, Natco is focusing on strategic acquisitions and R&D investments to drive sustainable growth and reduce volatility.

The transcript does not explicitly mention details about the current or expected order book or pending orders for Natco Pharma Limited. However, the following relevant points about product launches and pipelines can be noted: - Natco is working on building a pipeline with several exclusives expected to launch between FY '27 and '28, contributing to revenue growth of 15-25%. - Filings and launches planned include semaglutide (launch timing uncertain), ibrutinib, olaparib, carfilzomib, and others with potential exclusivities up to 7-8 years. - Brazil subsidiary expects growth from about INR280 crores to INR55-60 million in earnings this year. - Canada business (~INR229 crores this year) to grow 10-15%, with oncology launches expected in '27-'28. - South Africa business included as part of the diversified revenue stream. - No specific order book or pending order figures disclosed; focus remains on acquisitions and geographical diversification to stabilize revenues. Hence, no concrete current or expected order book numbers are provided in the available transcript.